At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 89 enrolled
Drug / intervention
Evolocumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics
In Brief
A Phase 3 clinical trial evaluating Evolocumab, Atorvastatin, and 2 other interventions for Primary Hyperlipidemia and Mixed Dyslipidemia. Completed, enrolled 89 participants across 2 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionFeb 2015
Study CompletionMar 2015
TodayJul 2026
First PostedJul 15, 2014
Enrollment StartJul 8, 2014
Primary CompletionFeb 13, 2015
Study CompletionMar 5, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.0 years ago
Interventions
Evolocumabbiological
Administered by subcutaneous injection
Atorvastatindrug
Administered by mouth
Placebo to Evolocumabdrug
Administered by subcutaneous injection
Placebo to Atorvastatindrug
Administered by mouth